The 22 most recent market catalysts affecting $MMED, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 85
Mobia Medical Reports Third Quarter 2026 Financial Results
Mobia Medical's Q3 2026 earnings report shows a significant 73% year-over-year revenue increase to $15.6 million, driven by the Vivistim Paired VNS System. This strong performance …
Nov 3, 2026
Corporate Catalyst
Neutral
Impact 55
MiniMed Appoints Dr. David Segal as Chief Medical Officer
MiniMed Group, Inc., recently spun off from Medtronic, has appointed Dr. David Segal as its Chief Medical Officer. This is a significant leadership addition for the newly independe…
Oct 15, 2026
Corporate Catalyst
Neutral
Impact 55
MiniMed Names Kevin E. Lofton Board Chair, Effective Separation From Medtronic
This 8-K filing confirms the final board composition for MiniMed following its separation from Medtronic. The announcement of Kevin E. Lofton as Board Chair and the addition of Amy…
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 55
Jefferies Initiates Coverage On Minimed Group with Hold Rating, Announces Price Target of $22
Jefferies analyst Michael Toomey has initiated coverage on Minimed Group (MMED) with a 'Hold' rating and a $22 price target. This event provides the market with a new professional …
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $28
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Minimed Group (MMED) and raised the price target from $26 to $28. This action signals continued confidence in th…
Oct 7, 2026
Corporate Catalyst
Neutral
Impact 55
Barclays Initiates Coverage On Minimed Group with Equal-Weight Rating, Announces Price Target of $22
Barclays analyst Christopher Pasquale initiated coverage on Minimed Group (MMED) with an 'Equal-Weight' rating and a $22 price target. This event is significant as it introduces a …
Oct 5, 2026
Corporate Catalyst
Bullish
Impact 55
MiniMed Study Links More Alert Responses To Better Diabetes Control
MiniMed (MMED) released clinical trial data showing that its Smart MDI system, which integrates a smart insulin pen with a continuous glucose monitor, led to an 8.1 percentage poin…
Sep 24, 2026
Corporate Catalyst
Neutral
Impact 65
Truist Securities Initiates Coverage On Minimed Group with Buy Rating, Announces Price Target of $29
Truist Securities initiating coverage on Minimed Group with a 'Buy' rating and a $29 price target is a positive development for the company. This action indicates that a new instit…
Sep 14, 2026
Corporate Catalyst
Neutral
Impact 85
MiniMed Files Form S-4 with SEC For Medtronic Exchange Offer Covering 225M Shares of MiniMed Common Stock
MiniMed announced the filing of its Form S-4 registration statement with the SEC. This filing is in connection with Medtronic's offer to exchange up to 225,361,295 shares of MiniMe…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 55
Morgan Stanley Maintains Overweight on Minimed Group, Raises Price Target to $21
Morgan Stanley analyst Kallum Titchmarsh has updated their coverage on Minimed Group, maintaining an 'Overweight' rating and raising the price target from $19 to $21. This action s…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on Minimed Group, Raises Price Target to $26
Citigroup analyst Joanne Wuensch maintained a 'Buy' rating on Minimed Group (MMED) and raised the price target from $23 to $26. This action signals increased confidence from a prom…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
Evercore ISI Group Maintains Outperform on Minimed Group, Raises Price Target to $27
Evercore ISI Group analyst Daniel Markowitz maintained an 'Outperform' rating on Minimed Group (MMED) and raised the price target from $20 to $27. This action signals increased con…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
Wells Fargo Maintains Overweight on Minimed Group, Raises Price Target to $26
Wells Fargo analyst Larry Biegelsen has maintained an 'Overweight' rating on Minimed Group (MMED) and raised the price target from $22 to $26. This action signals continued confide…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results
MiniMed Group's Q1 sales of $843 million significantly surpassed analyst consensus estimates of $827.065 million, representing a robust 16.6% year-over-year increase. This strong p…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
UBS Maintains Buy on Minimed Group, Raises Price Target to $28
This 8-K filing discloses that UBS analyst Patrick Wood has reiterated a 'Buy' rating on Minimed Group (MMED) and raised the price target from $25 to $28. This is a positive develo…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 60
Mizuho Maintains Outperform on Minimed Group, Raises Price Target to $26
Mizuho analyst Anthony Petrone maintained an 'Outperform' rating on Minimed Group (MMED) and raised the price target from $21 to $26. This action signals increased confidence from …
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 55
B of A Securities Maintains Buy on Minimed Group, Raises Price Target to $28
B of A Securities analyst Travis Steed has maintained a 'Buy' rating on Minimed Group (MMED) and raised the price target from $24 to $28. This action signals continued confidence i…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 55
BTIG Maintains Buy on Minimed Group, Raises Price Target to $28
BTIG analyst Marie Thibault maintained a 'Buy' rating on Minimed Group (MMED) and raised the price target from $25 to $28. This action signals increased confidence from the analyst…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
MiniMed shares are trading higher after the company reported better-than-expected Q1 sales results.
The better-than-expected Q1 sales for MiniMed are a significant corporate catalyst, directly impacting the company's stock positively. This strong performance suggests healthy dema…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Minimed Group Q1 Sales $843.000M Beat $827.065M Estimate
Minimed Group announced Q1 sales of $843 million, surpassing the consensus estimate of $827.065 million by 1.93%. This beat, coupled with a significant 16.60% year-over-year growth…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 85
Mobia Medical shares are trading higher after the company announced the addition of Vagus Nerve Stimulation to the updated AHA stroke guidelines.
The inclusion of Vagus Nerve Stimulation (VNS) in the updated AHA stroke guidelines is a significant corporate catalyst for Mobia Medical. This endorsement from a reputable medical…
Aug 28, 2026
Corporate Catalyst
Bearish
Impact 75
Top Wall Street Forecasters Revamp MiniMed Group Expectations Ahead Of Q1 Earnings
MiniMed Group (MMED) is facing a challenging Q1 earnings report, with consensus estimates for EPS at 9 cents, a sharp decline from 35 cents last year, and revenue projected at $828…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.